文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2019/20年欧洲DRIVE平台品牌特异性流感疫苗效果估计

Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
PubMed 文献 · Vaccine · 2021-06-03

DRIVE平台在2019/20年度通过四个初级保健和八个医院为基础的测试阴性设计研究及一个队列研究,估计品牌特异性流感疫苗效果。结果显示,Vaxigrip Tetra在儿童中效果为61%,在≤64岁成人中为32%;Fluad在≥65岁成人中为52%。队列研究中,2-6岁儿童Fluenz Tetra和Vaxigrip Tetra效果分别为68%和71%,≥65岁成人Vaxigrip Tetra效果为29%。

要点

  • Vaxigrip Tetra在初级保健儿童中IVE为61%,≤64岁成人为32%。
  • Fluad在住院≥65岁成人中IVE为52%。
  • 2-6岁儿童Fluenz Tetra和Vaxigrip Tetra IVE分别为68%和71%。

核心结论

  • 品牌特异性流感疫苗效果估计可用于公共卫生和监管目的。

研究设计与样本

  • 四个初级保健测试阴性设计研究(奥地利、英格兰、意大利两个)。
  • 八个医院测试阴性设计研究(芬兰、法国、意大利、罗马尼亚、西班牙四个)。
  • 一个基于人群的队列研究(芬兰)。

主要发现

  • 测试阴性设计研究纳入3531例病例(351例接种疫苗)和5546例对照(1415例接种疫苗)。
  • Vaxigrip Tetra在初级保健儿童中针对任何流感IVE为61%(95%CI 38-77),≤64岁成人为32%(95%CI -13-59)。
  • Fluad在住院≥65岁成人中IVE为52%(95%CI 27-68)。
  • 队列研究覆盖511854人年,2-6岁儿童Fluenz Tetra IVE为68%(95%CI 58-75),Vaxigrip Tetra为71%(95%CI 56-80)。
  • ≥65岁成人Vaxigrip Tetra IVE为29%(95%CI 20-36)。

关键数值与推荐

  • 年龄分层为6月-17岁、18-64岁、≥65岁。
  • 混杂调整包括年龄、性别和日历时间。
  • 研究期间截断于2020年2月29日。

临床怎么用

  • 品牌特异性IVE数据可支持疫苗政策制定和监管决策。

局限性

  • COVID-19大流行影响所有研究点的流感监测,研究期被截断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DRIVE (Development of Robust and Innovative Vaccine Effectiveness) is an IMI funded public-private platform that aims to annually estimate brand-specific influenza vaccine effectiveness (IVE), for public health and regulatory purposes. IVE analyses and reporting are conducted by public partners in the consortium. In 2019/20, four primary care-based test-negative design (TND) studies (Austria, England, Italy (n = 2)), eight hospital-based TND studies (Finland, France, Italy, Romania, Spain (n = 4)), and one population-based cohort study (Finland) were conducted. The COVID-19 pandemic affected influenza surveillance in all participating study sites, therefore the study period was truncated on February 29, 2020. Age-stratified (6 m-17y, 18-64y, ≥65y), confounder-adjusted, site-specific adjusted IVE estimates were calculated and pooled through meta-analysis. Parsimonious confounder-adjustment was performed, adjusting the estimates for age, sex and calendar time. TND studies included 3531 cases (351 vaccinated) and 5546 controls (1415 vaccinated) of all ages. IVE estimates were available for 8/11 brands marketed in Europe in 2019. Most children and adults < 64y were captured in primary care setting and the most frequently observed vaccine brand was Vaxigrip Tetra. The estimate against any influenza for Vaxigrip Tetra in primary care setting was 61% (95%CI 38-77) in children and 32% (95%CI -13-59) in adults up to 64y. Most adults ≥ 65y were captured in hospital setting and the most frequently observed brand was Fluad, with an estimate of 52% (95%CI 27-68). The population-based cohort covered 511,854 person-years and two vaccine brands. In children aged 2-6y, the IVE against any influenza was 68% (95%CI 58-75) for Fluenz Tetra and 71% (56-80) for Vaxigrip Tetra. In adults ≥ 65y, IVE against any influenza was 29% (20-36) for Vaxigrip Tetra. DRIVE is a growing platform. Public health institutes with surveillance data and hospitals in countries with high influenza vaccine coverage are encouraged to join DRIVE.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Stuurman AL, Biccler J, Carmona A, et al. Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform. Vaccine. 2021. PMID: 34092427. doi:10.1016/j.vaccine.2021.05.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。